A multicenter, double-blind, parallel-group, placebo-controlled study of the effect on cognitive performance and safety/tolerability of SSR180711C for 4 weeks, using donepezil as calibrator, in patients with mild Alzheimer's disease.
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2014
At a glance
- Drugs SSR 180711 (Primary) ; Donepezil
- Indications Alzheimer's disease
- Focus Pharmacodynamics
- Sponsors Sanofi
- 03 May 2012 Additional locations (Italy, Spain, Sweden) added as reported by European Clinical Trials Database record.
- 22 Jul 2009 Actual patient number (1) added as reported by ClinicalTrials.gov.
- 22 Jul 2009 Planned end date changed from 1 Sep 2008 to 1 Jul 2008 as reported by ClinicalTrials.gov.